Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Renal Impairment

nab-P/C proved beneficial and tolerable in patients with advanced NSCLC and mild and moderate renal impairment.